Currently, liver transplantation has reached a level of maturity where it is considered an effective treatment for end-stage liver disease and can significantly prolong the survival time of patients. However, acute and chronic rejection remain major obstacles to its efficacy. Although long-term use of immunosuppressants can prevent rejection, it is associated with serious side effects and significant economic burden for patients. Therefore, the investigation of induced immune tolerance holds crucial theoretical significance and socio-economic value. In fact, the establishment of immune tolerance in liver transplantation is intricately linked to the unique innate immune system of the liver. Kupffer cells, as a crucial component of this system, play a pivotal role in maintaining the delicate balance between inflammatory response and immune tolerance following liver transplantation. The important roles of different functions of Kupffer cells, such as phagocytosis, cell polarization, antigen presentation and cell membrane proteins, in the establishment of immune tolerance after transplantation is comprehensively summarized in this paper. Providing theoretical basis for further study and clinical application of Kupffer cells in liver transplantation.
Significant advancements in our understanding and clinical treatment of cholangiocarcinoma (CCA) have been achieved over the past 5 years. Groundbreaking studies have illuminated the immune landscape and pathological characteristics of the tumor microenvironment in CCA. The development of immune- and metabolism-based classification systems has enabled a nuanced exploration of the tumor microenvironment and the origins of CCA, facilitating a detailed understanding of tumor progression modulation. Despite these insights, targeted therapies have not yet yielded satisfactory clinical results, highlighting the urgent need for innovative therapeutic strategies. This review delineates the complexity and heterogeneity of CCA, examines the current landscape of therapeutic strategies and clinical trials, and delves into the resistance mechanisms underlying targeted therapies. Finally, from a single-cell and spatial transcriptomic perspective, we address the challenge of therapy resistance, discussing emerging mechanisms and potential strategies to overcome this barrier and enhance treatment efficacy.
26 March 2020 in International Journal of Molecular Medicine
Multiple mechanisms are involved in regulating hepatic ischemia‑reperfusion injury (IRI), in which Kupffer cells (KCs), which are liver‑resident macrophages, play critical roles by regulating inflammation and the immune response. Suberoylanilide hydroxamic acid (SAHA), a pan‑histone deacetylase inhibitor, has anti‑inflammatory effects and induces autophagy. To investigate whether SAHA ameliorates IRI and the mechanisms by which SAHA exerts its effects, an orthotopic liver transplantation (OLT) rat model was established after treatment with SAHA. The results showed that SAHA effectively ameliorated OLT‑induced IRI by reducing M1 polarization of KCs through inhibition of the AKT/glycogen synthase kinase (GSK)3β/NF‑κB signaling pathway. Furthermore, the present study found that SAHA upregulates autophagy 5 protein (ATG5)/LC3B in KCs through the AKT/mTOR signaling pathway and inhibition of autophagy by knockdown of ATG5 in KCs partly impaired the protective effect of SAHA on IR‑injured liver. Therefore, the current study demonstrated that SAHA reduces M1 polarization of KCs by inhibiting the AKT/GSK3β/NF‑κB pathway and upregulates autophagy in KCs through the AKT/mTOR signaling pathway, which both alleviate OLT‑induced IRI. The present study revealed that SAHA may be a novel treatment for the amelioration of OLT‑induced IRI.
Background: Acute rejection (AR) is a major determinant of poor prognosis after liver transplantation (LT), and macrophage M1-polarization can induce AR. Urokinase-type plasminogen activator (PLAU) has been implicated in the regulation of several liver diseases, but its role in AR remains unclear. Methods: In this study, through bioinformatics analysis and transcriptome sequencing, we find that PLAU and prostaglandin-endoperoxide synthase 2 (Ptgs2) can regulate macrophage polarization. To elucidate the effects of PLAU and Ptgs2 on AR, dynamic changes in PLAU and Ptgs2 expression are detected in both peripheral blood mononuclear cells (PBMCs) from clinical LT patients and hepatic macrophages from LT rats. Subsequently, to investigate the specific regulatory roles in macrophage M1-polarization and AR, downregulating PLAU and Ptgs2 rescue experiments are conducted in vivo and in vitro . Finally, potential signaling pathways are further identified through KEGG enrichment analysis. Results: The expression of PLAU and Ptgs2 is increased in PBMCs from LT patients and in macrophages from LT rats, and most significantly on postoperative day 7. Downregulating PLAU alleviates AR and suppresses M1-polarization of macrophages. However, Ptgs2 rescue exacerbates AR and promotes M1-polarization of macrophages. The potential mechanism involves regulating the Protein kinase B/Nuclear factor kappa B (AKT/NF-κB) pathway. Conclusion: In summary, downregulated the PLAU/Ptgs2 axis can attenuate AR by regulating macrophage polarization, offering a promising new therapeutic target for preventing and treating AR.